Glaritus 100IU Injection 1X10ml

Description

Glaritus 100IU Injection is a combination medicine used to improve blood sugar control in adults with type 2 diabetes when diet, exercise, and a single diabetes medicine are not enough. it combines two different medicines that work in complementary ways: insulin glargine, which provides long-acting basal insulin coverage over many hours, and lixisenatide, which helps the body lower blood sugar after meals and supports overall glucose control. because these medicines act through different mechanisms, the combination can help reduce both fasting blood sugar and post-meal spikes.

insulin glargine is a long-acting insulin analog. it is designed to release slowly after injection, helping maintain a more stable background level of insulin throughout the day and night. this is especially important in type 2 diabetes, where the body either does not produce enough insulin or does not use insulin properly. by replacing or supplementing insulin, it helps glucose move from the bloodstream into the body’s cells for energy and helps reduce excessive glucose production by the liver.

lixisenatide is a glp-1 receptor agonist, which means it mimics the action of a natural hormone involved in blood sugar regulation. it stimulates insulin release when blood sugar is elevated, reduces glucagon secretion, and slows stomach emptying, which helps blunt the rise in blood sugar after meals. it may also reduce appetite in some people, which can support weight-related benefits for certain patients. however, this medicine is not intended for type 1 diabetes or diabetic ketoacidosis, and it should be used only under the guidance of a healthcare professional.

this combination is generally prescribed for adults with type 2 diabetes who need stronger glucose-lowering treatment than lifestyle changes alone or who are not adequately controlled on oral medicines or basal insulin alone. it is often considered when both fasting and post-meal glucose need improvement. because it contains insulin, there is a risk of hypoglycemia, and because it contains a glp-1 receptor agonist, gastrointestinal side effects are common, especially when starting treatment or increasing therapy. careful monitoring is important to use it safely and effectively.

ingredients

• insulin glargine: a long-acting insulin that provides steady basal insulin coverage. it helps lower fasting and between-meal blood sugar by supporting glucose uptake into cells and reducing glucose production by the liver. its prolonged action allows once-daily use in many treatment plans, helping maintain more stable blood glucose control over time.
• lixisenatide: a glp-1 receptor agonist that improves blood sugar control after meals and in the fasting state. it enhances glucose-dependent insulin secretion, lowers glucagon levels when blood sugar is high, and slows gastric emptying, which helps reduce post-meal glucose surges. it may also contribute to a feeling of fullness.
• inactive ingredients: the exact excipients may vary by brand or formulation. these components help stabilize the medicine, maintain sterility, and support proper delivery through injection. patients with allergies or sensitivities should review the product label and consult a pharmacist or clinician if needed.

key uses

• type 2 diabetes mellitus: used to improve blood sugar control in adults with type 2 diabetes when a single medication is not enough. it helps address both fasting and meal-related glucose elevations.
• combination therapy when multiple mechanisms are needed: helpful for patients who may benefit from both basal insulin action and glp-1 receptor agonist effects in one treatment approach, potentially reducing the need for separate injections.
• when blood sugar remains uncontrolled on existing therapy: may be prescribed if diet, exercise, and oral medications or basal insulin alone do not adequately control glucose levels. it is intended to support overall glycemic management, not to cure diabetes.

how to use

Glaritus 100IU Injection is given as a subcutaneous injection, meaning it is injected under the skin, not into a vein or muscle. it is usually administered once daily at about the same time each day, following the instructions provided by the prescribing clinician. the injection is typically given in the abdomen, thigh, or upper arm, and the injection site should be rotated to reduce the risk of skin irritation, thickening, or lumps under the skin. the medicine should be used exactly as prescribed, and patients should not change the timing, amount, or frequency without medical advice.

it is important to learn the correct injection technique from a healthcare professional before using this medicine at home. the pen or device should be checked carefully, and the solution should be inspected according to product instructions. general diabetes care also matters: regular blood sugar monitoring, following a meal plan, staying physically active as advised, and attending follow-up appointments are all important. because the medicine can lower blood sugar, meals should not be skipped unless specifically advised by a clinician. if other diabetes medicines, especially insulin or sulfonylureas, are used together, the risk of low blood sugar may be higher and may require monitoring or adjustment by the prescriber.

safety information

• warnings: this medicine can cause low blood sugar, especially if meals are delayed or skipped, alcohol is consumed, exercise is increased unexpectedly, or other glucose-lowering medicines are used together. severe hypoglycemia can be dangerous and may cause confusion, fainting, seizures, or loss of consciousness. it should not be used to treat type 1 diabetes or diabetic ketoacidosis. pancreatitis has been reported with glp-1 receptor agonists, so persistent severe abdominal pain, with or without vomiting, needs urgent medical evaluation. dehydration can occur if nausea, vomiting, or diarrhea is significant.
• side effects: common effects include nausea, vomiting, diarrhea, decreased appetite, stomach discomfort, constipation, injection-site reactions, and low blood sugar. some people may experience weight loss, headache, dizziness, or mild swelling. serious side effects may include severe hypoglycemia, pancreatitis, allergic reactions, gallbladder problems, kidney function worsening, and, rarely, severe gastrointestinal symptoms that lead to dehydration.
• precautions: use caution in people with a history of pancreatitis, kidney disease, severe gastrointestinal disease, or frequent hypoglycemia. it may not be suitable for those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, depending on product labeling and clinical judgment. extra care is needed in older adults, people with irregular eating patterns, and those who have trouble recognizing hypoglycemia.
• pregnancy/breastfeeding: blood sugar control is very important during pregnancy, but the safety of this combination during pregnancy may be limited and should be assessed by a clinician. breastfeeding safety should also be discussed with a healthcare professional, as treatment needs may differ during lactation. do not use during pregnancy or breastfeeding without medical guidance.
• interactions: other insulin products, sulfonylureas, and some diabetes medicines can increase the risk of low blood sugar. alcohol can also increase hypoglycemia risk and may make blood sugar harder to predict. medicines that affect stomach emptying or gastrointestinal function may alter absorption of oral medications. always tell the healthcare provider about all prescription drugs, over-the-counter products, supplements, and alcohol use.

additional information

• storage: store according to the product label, usually in a refrigerator before first use and protected from freezing and excessive heat. do not freeze the medicine, and do not use it if it has been frozen. after opening or first use, some products may be kept at room temperature for a limited time as directed by the manufacturer. keep the pen or container capped and out of direct light. always follow the specific storage instructions for the exact product.
• missed dose: if a dose is missed, follow the instructions given by the prescribing clinician or the product labeling. in general, it should not be doubled to make up for a missed dose. blood sugar should be monitored, and advice should be sought if there is uncertainty about timing or if multiple doses have been missed.
• overdose: an overdose can cause severe hypoglycemia, which may lead to sweating, shakiness, rapid heartbeat, hunger, confusion, blurred vision, weakness, or loss of consciousness. severe nausea, vomiting, and dehydration may also occur. if overdose is suspected, seek emergency medical help immediately. fast-acting sugar may be needed if the person is conscious, but severe cases may require urgent medical treatment and monitoring.
• habit forming: no. Glaritus 100IU Injection is not habit-forming and does not cause dependence. however, it must be used regularly and only as prescribed to maintain blood sugar control safely.

frequently asked questions

this information is for educational purposes only and should not be considered medical advice. always consult a qualified healthcare professional before use.